Most important take away

Psychedelic therapy is emerging as a legitimate, FDA-tracked healthcare category — not a hype trade — with Compass Pathways (CMPS) leading the way after its Phase 3 psilocybin trials showed a well-tolerated safety profile, sending the stock up over 23%. Unlike traditional daily-use antidepressants, this is an interventional model (one to six sessions) targeting the massive treatment-resistant mental health market of roughly 100 million people globally with depression alone, creating a fundamentally different investment thesis that investors need to understand before entering the space.

Summary

Stocks and Investments Mentioned

• Compass Pathways (CMPS): Publicly traded. Stock rose over 23% after Phase 3 trial results for COMP 360 (synthetic psilocybin). They are first-to-market, which is a significant competitive advantage. Their study design isolated the drug effect from therapy (calling it “psychological support”), making it more palatable to the FDA than the earlier MDMA approach.
• AbbVie (ABBV): Acquired Gilgamesh Pharmaceuticals (August 2025) for a psychedelic compound called Brettatecellicin, signaling big pharma is beginning to take early positions.
• Spravato (Johnson & Johnson / Janssen): A ketamine analog already brought to market by big pharma, representing a safer earlier bet in this space since ketamine was already well-established.
• MDMA therapy: Had an FDA rejection in 2024 due to study design issues (therapy was too embedded in the research protocol). This is a cautionary tale for investors about regulatory risk.

Actionable Insights

1. Understand the interventional model before investing. Psychedelic therapy is not a daily-use drug business. It is closer to procedures like TMS (transcranial magnetic stimulation) — patients undergo one to six sessions, not ongoing prescriptions. This fundamentally changes revenue models and comparisons to traditional pharma.

2. Watch for FDA approval of psilocybin first. Compass Pathways is furthest along in Phase 3 trials and has designed its study to address the FDA’s prior concerns with MDMA. First-to-market approval could be a major catalyst.

3. Consider the service delivery side, not just drug makers. The real revenue may be in clinics and treatment centers, not the drug itself. Treatments cost $10,000-$20,000 per patient, while the drug costs $500-$800. Investors who can identify or invest in the service infrastructure may capture more value.

4. Be aware of biopharma failure rates. Many drugs do not make it through FDA approval. The 2024 MDMA rejection is a reminder that regulatory risk is real in this space.

5. Big pharma is not yet threatened but is watching. Traditional antidepressant makers still hold the lion’s share of patients. Psychedelic therapy currently targets treatment-resistant cases where conventional drugs have already failed. This means the space is more complementary than disruptive in the near term, but could shift over 10-15 years.

6. First-mover advantage matters, but so does session efficiency. Psilocybin sessions last 5-6 hours, which is operationally demanding for clinics. Shorter-acting compounds in the pipeline could eventually offer competitive advantages over psilocybin, so watch the pipeline beyond just CMPS.

7. The addressable market is enormous. Treatment-resistant depression alone affects roughly 100 million people globally (one-third of all depression patients). This is the core market for psychedelic therapy and represents significant unmet medical need.

Chapter Summaries

Introduction and Market Context: Producer Matt Greer sets up the episode by noting Compass Pathways (CMPS) stock jumped 23% on Phase 3 trial news and introduces guests Keith Curlander and Dr. Will Vanderveer, co-founders of the Integrative Psychiatry Institute.

What Investors Get Wrong About Psychedelic Therapy: Curlander explains that psychedelic therapy is interventional (one to six sessions), not daily-use pharma. Vanderveer adds that the treatment-resistant depression market alone is 100 million people globally, and current treatments fail to produce durable results.

How Psychedelic Therapy Works: The treatment combines psychedelic medicines with structured therapy in preparation, session, and integration phases. The medicines both amplify the therapeutic process and produce biological changes in the brain, offering a “two-for-one” that conventional antidepressants do not provide. The approach accesses the unconscious mind to address root causes rather than just suppressing symptoms.

From Counterculture to FDA Trials: The tipping point came from the veteran mental health crisis — 30,000 veteran suicides between 2001-2014 compared to 7,000 combat deaths. This imperative forced the medical establishment to explore unconventional approaches.

Red Flags for Investors: Not all drugs make it through FDA. The 2024 MDMA rejection is instructive. Compass Pathways structured its psilocybin study differently (isolating drug effect, calling therapy “psychological support”) to improve FDA odds. The service/clinic side may be where the real money is, not just the drug companies.

Competitive Moats and Advantages: First-to-market is valuable, but psilocybin’s 5-6 hour session length is operationally challenging for clinics. Shorter-acting compounds in the pipeline could disrupt even psilocybin’s position.

Case Study — “Charles” the Combat Veteran: A 24-year-old veteran with moral injury from Iraq went through the VA system and conventional medications (“combat cocktail”) with no benefit. Through MDMA-assisted therapy, he accessed self-compassion, forgiveness, and post-traumatic growth — moving beyond symptom elimination to becoming a productive contributor to society.

Big Pharma’s Response: Large pharma companies are not yet threatened but are watching. AbbVie’s acquisition of Gilgamesh for a psychedelic compound and J&J’s Spravato (ketamine analog) are early signals. Smaller companies are doing the grassroots work of getting psychedelics through regulatory approval.

Key Takeaway from the Authors: Anyone can heal given the right supports. Psychedelic therapy represents an opportunity not just to eliminate symptoms but to achieve post-traumatic growth — becoming more well than before the illness. Mental health conditions have known causes that can be addressed at the root, rather than just managed.